Fractyl Health (NASDAQ:GUTS – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
Institutional & Insider Ownership
91.0% of Pulmonx shares are held by institutional investors. 5.7% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Fractyl Health and Pulmonx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fractyl Health | $97,000.00 | 1,076.03 | -$77.09 million | ($12.19) | -0.18 |
| Pulmonx | $68.68 million | 3.71 | -$60.84 million | ($1.47) | -4.39 |
Analyst Recommendations
This is a summary of current ratings and target prices for Fractyl Health and Pulmonx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fractyl Health | 0 | 0 | 3 | 0 | 3.00 |
| Pulmonx | 0 | 1 | 5 | 0 | 2.83 |
Fractyl Health currently has a consensus target price of $22.00, suggesting a potential upside of 913.82%. Pulmonx has a consensus target price of $14.67, suggesting a potential upside of 127.04%. Given Fractyl Health’s stronger consensus rating and higher possible upside, equities analysts clearly believe Fractyl Health is more favorable than Pulmonx.
Profitability
This table compares Fractyl Health and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fractyl Health | -64,849.48% | N/A | -57.21% |
| Pulmonx | -72.01% | -53.88% | -33.47% |
Summary
Pulmonx beats Fractyl Health on 8 of the 13 factors compared between the two stocks.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
